Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.

Hoot MR, Sypek EI, Reilley KJ, Carey AN, Bidlack JM, McLaughlin JP.

Behav Pharmacol. 2013 Apr;24(2):144-52. doi: 10.1097/FBP.0b013e32835f3d2f.

PMID:
23412114
2.
4.

In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile.

Kuo A, Wyse BD, Meutermans W, Smith MT.

Br J Pharmacol. 2015 Jan;172(2):532-48. doi: 10.1111/bph.12696.

5.

Chronic morphine administration results in tolerance to delta opioid receptor-mediated antinociception.

Pradhan AA, Siau C, Constantin A, Clarke PB.

Neuroscience. 2006 Aug 25;141(2):947-54.

PMID:
16716526
6.
7.

Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors.

Vanderah TW, Bernstein RN, Yamamura HI, Hruby VJ, Porreca F.

J Pharmacol Exp Ther. 1996 Jul;278(1):212-9.

PMID:
8764354
8.
9.

MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.

Matsumoto K, Takayama H, Narita M, Nakamura A, Suzuki M, Suzuki T, Murayama T, Wongseripipatana S, Misawa K, Kitajima M, Tashima K, Horie S.

Neuropharmacology. 2008 Aug;55(2):154-65. doi: 10.1016/j.neuropharm.2008.05.003.

PMID:
18550129
10.

Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects.

Vidal-Torres A, de la Puente B, Rocasalbas M, Touriño C, Bura SA, Fernández-Pastor B, Romero L, Codony X, Zamanillo D, Buschmann H, Merlos M, Baeyens JM, Maldonado R, Vela JM.

Eur J Pharmacol. 2013 Jul 5;711(1-3):63-72. doi: 10.1016/j.ejphar.2013.04.018.

PMID:
23632394
12.

Activation of TREK-1 by morphine results in analgesia without adverse side effects.

Devilliers M, Busserolles J, Lolignier S, Deval E, Pereira V, Alloui A, Christin M, Mazet B, Delmas P, Noel J, Lazdunski M, Eschalier A.

Nat Commun. 2013;4:2941. doi: 10.1038/ncomms3941.

PMID:
24346231
13.
14.

Potentiation of morphine-induced mechanical antinociception by σ₁ receptor inhibition: role of peripheral σ₁ receptors.

Sánchez-Fernández C, Nieto FR, González-Cano R, Artacho-Cordón A, Romero L, Montilla-García Á, Zamanillo D, Baeyens JM, Entrena JM, Cobos EJ.

Neuropharmacology. 2013 Jul;70:348-58. doi: 10.1016/j.neuropharm.2013.03.002.

PMID:
23524304
16.

Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice.

Shu H, Hayashida M, Arita H, Huang W, Zhang H, An K, Wu G, Hanaoka K.

J Pharmacol Exp Ther. 2011 Aug;338(2):579-87. doi: 10.1124/jpet.111.179879.

17.
18.

Intrathecal atipamezole augments the antinociceptive effect of morphine in rats.

Lilius TO, Rauhala PV, Kambur O, Rossi SM, Väänänen AJ, Kalso EA.

Anesth Analg. 2012 Jun;114(6):1353-8. doi: 10.1213/ANE.0b013e31824c727d.

PMID:
22556211
19.

Tramadol antinociception is potentiated by clonidine through α₂-adrenergic and I₂-imidazoline but not by endothelin ET(A) receptors in mice.

Andurkar SV, Gendler L, Gulati A.

Eur J Pharmacol. 2012 May 15;683(1-3):109-15. doi: 10.1016/j.ejphar.2012.03.016.

PMID:
22449379
20.

Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors.

Wong CS, Cherng CH, Luk HN, Ho ST, Tung CS.

Eur J Pharmacol. 1996 Feb 15;297(1-2):27-33.

PMID:
8851162
Items per page

Supplemental Content

Support Center